Fig. 3From: Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patientsValidation of selected candidate proteins by PRM-MS analysis. Differential expression of (a) PZP and (c) IGFBP3 in the T2DM + LAC and T2DM groups. ROC analysis of the diagnostic value of (b) PZP and (d) IGFBP3 for the detection of LAC in T2DM patientsBack to article page